THE WOODLANDS, Texas--(BUSINESS WIRE)--On December 15, 2009, Repros Therapeutics Inc. (NasdaqGM:RPRX) received notification from NASDAQ that it has not regained compliance with NASDAQ Listing Rules 5450(b)(2)(C) and 5450(b)(1). The first rule applies to the market value of publicly held shares and the latter is the requirement of a minimum of a $1 share price. The Company has until June 14, 2010 to rectify the $1 share price deficiency assuming that the Company’s appeal to remain listed is granted. Repros appealed the listing deficiency associated with Rule 5450 (b)(2)(C) in early December and the Company awaits the decision of the NASDAQ Listing Qualifications Panel. As part of the Repros appeal the Company requested its securities be moved to the NASDAQ Capital Market. There can be no assurance that the appeal will be successful thereby allowing Repros to continue to trade on a NASDAQ market.
